EU reimbursement: country variations in value assessment and the key routes to market entry
This article was originally published in Clinica
Executive Summary
Reimbursement of medical technology is linked to the value offered by the product. Some of this value is intrinsic to the technology and is constant across all EU markets; some varies by market according to the country's specific reimbursement rules, coding, current standard of care, professional practice, and differing unit costs. Dr Mark Charny of UK consultancy Translucency looks at which elements of value can apply across the EU, which are country-specific and how best to use value to access these markets